Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma

BACKGROUND: Recent genomic analyses revealed that druggable molecule targets were only detectable in approximately 6% of patients with nasopharyngeal carcinoma (NPC). However, a dependency on dysregulated CDK4/6–cyclinD1 pathway signaling is an essential event in the pathogenesis of NPC. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Zhichao, Lui, Vivian Wai Yan, Li, Yongshu, Jia, Lin, You, Chanping, Li, Xin, Piao, Wenying, Yuan, Hui, Khong, Pek Lan, Lo, Kwok Wai, Cheung, Lydia Wai Ting, Lee, Victor Ho Fan, Lee, Anne Wing Mui, Tsao, Sai Wah, Tsang, Chi Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690146/
https://www.ncbi.nlm.nih.gov/pubmed/33243298
http://dx.doi.org/10.1186/s13046-020-01763-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690146/
https://www.ncbi.nlm.nih.gov/pubmed/33243298
http://dx.doi.org/10.1186/s13046-020-01763-z

Ejemplares similares